Physician profile
Alfred J Fleming
NPI 1396852422
$1,369.23
in general payments reported to CMS, 2019-2025
12 companies · $243 in 2025
The $243 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $151 · 2021: $94.21 · 2022: $12.60 · 2023: $275 · 2024: $212 · 2025: $243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $730.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cochlear Americas | $391.09 | 2019-2025 | Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode, Osia Osi300 Implant, Baha |
| Acclarent, INC | $293.65 | 2019-2022 | |
| Optinose US, INC. | $191.61 | 2019-2025 | |
| Amgen INC. | $134.85 | 2025 | Tepezza |
| Depuy Synthes Sales INC. | $107.76 | 2020 | |
| Intersect Ent, INC. | $102.17 | 2019 | |
| Stryker Corporation | $68.47 | 2019-2025 | Audion Et Dilation System |
| Astrazeneca Pharmaceuticals LP | $21.71 | 2025 | Tezspire |
| Adma Biomanufacturing LLC | $17.57 | 2021 | |
| Smith+Nephew, INC. | $13.70 | 2023 | Tula |
| Paratek Pharmaceuticals, INC. | $13.56 | 2025 | Xhance |
| Genzyme Corporation | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfred Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.